News

Filter

1 to 9 of 12 results

Novartis finally gets Alcon; vildagliptin now available for elderly type 2 diabetics in UK

08-04-2011

In what looks to be the last hurdle for Swiss drug major Novartis (NOVN: VX) to take full control of…

AlconDiabetesMergers & AcquisitionsNovartisOphthalmicsPharmaceuticalRegulationvildagliptin

Novartis finally reaches agreement with Alcon’s minority shareholders for full control

15-12-2010

Ending a long struggle to gain 100% control of eye care specialist Alcon (NYSE: ACL), Swiss drug major…

AlconMergers & AcquisitionsNovartisOpthalmicsPharmaceutical

Novartis in $422.5 million settlement over US illegal marketing; cites Swiss law expert on Alcon IDC’s legal position in proposed merger

01-10-2010

Swiss drug major Novartis (NOVN: VX) says its US subsidiary, Novartis Pharmaceuticals Corp (NPC), has…

AlconLegalMergers & AcquisitionsNovartisOphthalmicsPharmaceutical

Bausch & Lomb moves to acquire Miochol-E from Novartis as required by US competition authority

07-09-2010

In order to comply with US anti-trust requirements imposed by the Federal Trade Commission to complete…

AlconBausch & LombLegalMergers & AcquisitionsMiochol-ENovartisOphthalmicsPharmaceutical

UK's NICE gives final 'no' to NHS use of Novartis cancer drug Glivec; Novartis now holds 77% of Alcon

26-08-2010

In another negative decision on the use of cancer drugs on the National Health Service in England and…

AlconGleevecGlivecMergers & AcquisitionsNovartisOncologyPharmaceuticalRegulation

Novartis buy of Alcon moves forward, but USA and China competition authorities call for divestments

17-08-2010

Swiss drug major Novartis will be required to sell an injectable eye care drug used in cataract surgery…

AlconMergers & AcquisitionsNovartisOphthalmicsPharmaceutical

Novartis must get Alcon IDC approval for buyout, says Swiss corporate governance expert

29-06-2010

Fuelling further delay in Swiss drug major Novartis’ plans to buy 100% of ophthalmic drugs and eye…

AlconMergers & AcquisitionsNovartisOphthalmicsPharmaceutical

Alcon Independent Director Committee says Novartis’ offer still grossly inadequate, especially given Alcon’s strong earnings

29-04-2010

The Independent Director Committee of Switzerland-based ophthalmics group Alcon yesterday reiterated…

AlconMergers & AcquisitionsNovartisOphthalmicsPharmaceutical

1 to 9 of 12 results

COMPANY SPOTLIGHT

Menarini

Back to top